These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 38641067)

  • 21. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
    Terns MP
    Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure of the miniature type V-F CRISPR-Cas effector enzyme.
    Takeda SN; Nakagawa R; Okazaki S; Hirano H; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Nishimasu H; Nureki O
    Mol Cell; 2021 Feb; 81(3):558-570.e3. PubMed ID: 33333018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.
    East-Seletsky A; O'Connell MR; Knight SC; Burstein D; Cate JH; Tjian R; Doudna JA
    Nature; 2016 Oct; 538(7624):270-273. PubMed ID: 27669025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes.
    Koonin EV; Makarova KS
    RNA Biol; 2013 May; 10(5):679-86. PubMed ID: 23439366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
    Meeske AJ; Marraffini LA
    Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target DNA recognition and cleavage by a reconstituted Type I-G CRISPR-Cas immune effector complex.
    Majumdar S; Ligon M; Skinner WC; Terns RM; Terns MP
    Extremophiles; 2017 Jan; 21(1):95-107. PubMed ID: 27582008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural analyses of the CRISPR protein Csc2 reveal the RNA-binding interface of the type I-D Cas7 family.
    Hrle A; Maier LK; Sharma K; Ebert J; Basquin C; Urlaub H; Marchfelder A; Conti E
    RNA Biol; 2014; 11(8):1072-82. PubMed ID: 25483036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CRISPR proteins: Counterattack of phages on bacterial defense (CRISPR/Cas) system.
    Chaudhary K; Chattopadhyay A; Pratap D
    J Cell Physiol; 2018 Jan; 233(1):57-59. PubMed ID: 28247934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlling and enhancing CRISPR systems.
    Shivram H; Cress BF; Knott GJ; Doudna JA
    Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.
    Wang B; Zhang T; Yin J; Yu Y; Xu W; Ding J; Patel DJ; Yang H
    Mol Cell; 2021 Mar; 81(5):1100-1115.e5. PubMed ID: 33472057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding the Biologist's Toolkit with CRISPR-Cas9.
    Sternberg SH; Doudna JA
    Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
    Liu L; Pei DS
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutting it close: CRISPR-associated endoribonuclease structure and function.
    Hochstrasser ML; Doudna JA
    Trends Biochem Sci; 2015 Jan; 40(1):58-66. PubMed ID: 25468820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism.
    Liu L; Chen P; Wang M; Li X; Wang J; Yin M; Wang Y
    Mol Cell; 2017 Jan; 65(2):310-322. PubMed ID: 27989439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unravelling the structural and mechanistic basis of CRISPR-Cas systems.
    van der Oost J; Westra ER; Jackson RN; Wiedenheft B
    Nat Rev Microbiol; 2014 Jul; 12(7):479-92. PubMed ID: 24909109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SnapShot: CRISPR-RNA-guided adaptive immune systems.
    Carter J; Wiedenheft B
    Cell; 2015 Sep; 163(1):260-260.e1. PubMed ID: 26406380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.